FDA approves UCB’s nasal spray for American market

Nayzilam, UCB’s nasal spray for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity has been approved by the American Food and Drug administration (FDA).

This will be the first nasal spray for the treatment of seizure episodes. Read more here. (NL)

Leave a Reply

Your email address will not be published. Required fields are marked *